PORTLAND, Ore.--(BUSINESS WIRE)--CytoDyn Inc. (“CytoDyn”) (OTC QB: CYDY), a biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses, announced today that it has expanded the company’s online presence through the launch of an Arabic-language website.
Additionally, CytoDyn launches the first of a series of videos highlighting the company’s recent accomplishments and initiatives underway. The English-spoken video can be viewed on CytoDyn’s main website at http://www.cytodyn.com/about-us/.
The Arabic-language website will serve as an important tool in reaching CytoDyn’s global audience of stakeholders and investors. The launch of the website coincides with several other significant milestones for the company under the new management of interim President and CEO Dr. Nader Pourhassan and Chief Scientific Officer Dr. Richard Trauger, including CytoDyn’s acquisition of PRO 140 from Progenics Pharmaceuticals and clinical trials agreement with the Drexel University College of Medicine to conduct additional Phase II studies with PRO 140, an experimental humanized monoclonal antibody targeting the CCR5 receptor for the treatment of HIV infection. CytoDyn also recently moved the company’s corporate headquarters to Oregon, home to one of the United State’s most vibrant biotechnology corridors. The new website can be found at www.cytodyn-arabic.com.
“We are very pleased to be able to share our recent developments,” said Dr. Pourhassan. “This video and future videos as well as our new Arabic-language website will allow CytoDyn to tell the story of the company’s promising work to an even larger audience, including our investors, the HIV and AIDS advocacy community and our colleagues in the industry around the globe.”
The Company
CytoDyn is a biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses and other antibody applications. Its proprietary drug candidate Cytolin(R) is a monoclonal antibody that binds to CD11a, a cellular antigen that is a component of the cellular adhesion molecule LFA-1. With the addition of Pro 140, CytoDyn intends to explore the clinical development of cell-specific monoclonal antibodies as viral entry inhibitors to determine if they can perturb the natural course of HIV infection in persons infected with the Human Immunodeficiency Virus (‘HIV”). In addition, CytoDyn is exploring the possible application of its existing proprietary monoclonal antibody for the treatment of Feline Immunodeficiency Virus (“FIV”), a retroviral infection in cats. CytoDyn recently filed for a provisional patent for the use of these antibodies as well as selected small molecule antagonists and agonists for the treatment of FIV, and filed an application for registration of the trademark CytoFeline, intended for use in conjunction with veterinary preparations for the treatment of FIV. For more information about PRO 140, Cytolin(R), CytoFeline(TM) and the company please go to www.cytodyn.com.
Forward-Looking Statements
This press release includes forward-looking statements and forward-looking information within the meaning of United States securities laws. These statements and information represent CytoDyn’s intentions, plans, expectations and beliefs, and are subject to risks, uncertainties and other factors, of which many are beyond CytoDyn’s control. These factors could cause actual results to differ materially from such forward-looking statements or information. The words “believe,” “estimate,” “expect,” “intend,” “attempt,” “anticipate,” “foresee,” “plan,” and similar expressions and variations thereof, identify certain of such forward-looking statements or forward-looking information, which speak only as of the date on which they are made. CytoDyn disclaims any intention or obligation to publicly update or revise any forward-looking statements or forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable law. Readers are cautioned not to place undue reliance on these forward-looking statements or forward-looking information.
While it is impossible to identify or predict all such matters, these differences may result from, among other things, the inherent uncertainty of the timing and success of, and expense associated with, research, development, regulatory approval and commercialization of our products and product candidates, including the risks that clinical trials will not commence or proceed as planned; products appearing promising in early trials will not demonstrate efficacy or safety in larger-scale trials; future clinical trial data on our products and product candidates will be unfavorable; our products will not receive marketing approval from regulators or, if approved, fail to gain sufficient market acceptance to justify development and commercialization costs; competing products currently on the market or in development may reduce the commercial potential of our products; CytoDyn, our collaborators or others may identify side effects after the product is on the market; or efficacy or safety concerns regarding marketed products, whether or not scientifically justified, may lead to product recalls, withdrawals of marketing approval, reformulation of the product, additional pre-clinical testing or clinical trials, changes in labeling of the product, the need for additional marketing applications, or other adverse events.
We are also subject to additional risks and uncertainties, including risks associated with the actions of our corporate, academic and other collaborators and government regulatory agencies; risks from market forces and trends; potential product liability; intellectual property, litigation, environmental and other risks; and risks that current and pending patent protection for our products may be invalid, unenforceable or challenged, or fail to provide adequate market exclusivity. There are also substantial risks arising out of our need to raise additional capital to develop our products and satisfy our financial obligations; the highly regulated nature of our business, including government cost-containment initiatives and restrictions on third-party payments for our products; the highly competitive nature of our industry; and other factors set forth in our Annual Report on Form 10-K and other reports filed with the U.S. Securities and Exchange Commission.